Prediction of gestational diabetes mellitus and perinatal outcomes by plasma zonulin levels

Oral, Serkan; Çelik, Sebahattin; Akpak, Yaşam Kemal; Gölbaşı, Hakan; Bayraktar, Burak; Unver, Gokhan; Sahin, Sami; Yurtçu, Nazan; Çalışkan, Canan Soyer

doi:10.1007/s00404-022-06751-6

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between zonulin levels and impaired glucose metabolism has also been described in patients with obesity [ 62 , 141 , 142 , 143 , 144 ] or insulin resistance associated with polycystic ovary syndrome (PCOS) [ 145 , 146 ]. Moreover, it has recently been shown that elevated levels of zonulin could be a potential predictor of complications related to pregnancy, including gestational diabetes (GDM), intrahepatic cholestasis (ICP), hypertensive disorders (HDP), and adverse perinatal outcomes [ 131 , 147 , 148 , 149 , 150 , 151 , 152 ].…”

Section: Diseases Associated With Altered Zonulin Levelsmentioning

confidence: 99%

Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions

Veres-Székely

Szász

Pap

et al. 2023

IJMS

View full text Add to dashboard Cite

The relationship between dysbiosis and central nervous diseases has been proved in the last 10 years. Microbial alterations cause increased intestinal permeability, and the penetration of bacterial fragment and toxins induces local and systemic inflammatory processes, affecting distant organs, including the brain. Therefore, the integrity of the intestinal epithelial barrier plays a central role in the microbiota–gut–brain axis. In this review, we discuss recent findings on zonulin, an important tight junction regulator of intestinal epithelial cells, which is assumed to play a key role in maintaining of the blood–brain barrier function. In addition to focusing on the effect of microbiome on intestinal zonulin release, we also summarize potential pharmaceutical approaches to modulate zonulin-associated pathways with larazotide acetate and other zonulin receptor agonists or antagonists. The present review also addresses the emerging issues, including the use of misleading nomenclature or the unsolved questions about the exact protein sequence of zonulin.

show abstract